美国食品和药物管理局(ＦＤＡ)已经批准,将给抗结核病新药利福喷丁(Ｐｒｉｆｔｉｎ)颁发执照,这是25年内第一次。利福喷丁适用于肺结核,但须与其他抗结核药物联合应用。由于其疗程较传统药物短,有望提高患者的依从性。活动性肺结核的现有治疗方案至少需6～9个月疗程,且至少用3 For the first time in 25 years, the U.S. Food and Drug Administration (FDA) has already approved the drug to license Priftin, the new anti-tuberculosis drug. Rifapentin for tuberculosis, but with other anti-TB drugs in combination. Because of its shorter duration of treatment than traditional drugs, is expected to increase patient compliance. Existing treatment options for active tuberculosis require at least 6 to 9 months of treatment, with a minimum of 3